Linden Thomas Advisory Services LLC Has $2.01 Million Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Linden Thomas Advisory Services LLC cut its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 1.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 114,550 shares of the company’s stock after selling 1,341 shares during the quarter. Linden Thomas Advisory Services LLC’s holdings in Kiniksa Pharmaceuticals were worth $2,009,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Connor Clark & Lunn Investment Management Ltd. grew its stake in Kiniksa Pharmaceuticals by 59.9% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 256,932 shares of the company’s stock valued at $4,463,000 after buying an additional 96,288 shares during the last quarter. Acadian Asset Management LLC grew its stake in Kiniksa Pharmaceuticals by 916.6% in the 3rd quarter. Acadian Asset Management LLC now owns 226,181 shares of the company’s stock valued at $3,919,000 after buying an additional 203,933 shares during the last quarter. Schonfeld Strategic Advisors LLC grew its stake in Kiniksa Pharmaceuticals by 180.1% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 208,500 shares of the company’s stock valued at $3,622,000 after buying an additional 134,070 shares during the last quarter. Barclays PLC grew its position in Kiniksa Pharmaceuticals by 7.9% in the 3rd quarter. Barclays PLC now owns 175,525 shares of the company’s stock worth $3,048,000 after purchasing an additional 12,867 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in Kiniksa Pharmaceuticals by 13.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 146,568 shares of the company’s stock worth $2,546,000 after purchasing an additional 17,790 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Kiniksa Pharmaceuticals

In other news, CEO Sanj K. Patel sold 12,742 shares of the firm’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $21.49, for a total transaction of $273,825.58. Following the completion of the transaction, the chief executive officer now directly owns 70,594 shares of the company’s stock, valued at approximately $1,517,065.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Sanj K. Patel sold 5,582 shares of Kiniksa Pharmaceuticals stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $21.00, for a total transaction of $117,222.00. Following the completion of the transaction, the chief executive officer now directly owns 65,012 shares of the company’s stock, valued at approximately $1,365,252. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Sanj K. Patel sold 12,742 shares of Kiniksa Pharmaceuticals stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $21.49, for a total transaction of $273,825.58. Following the transaction, the chief executive officer now directly owns 70,594 shares of the company’s stock, valued at $1,517,065.06. The disclosure for this sale can be found here. In the last three months, insiders sold 33,109 shares of company stock valued at $709,929. Company insiders own 54.23% of the company’s stock.

Analyst Ratings Changes

KNSA has been the topic of several research analyst reports. Wedbush restated an “outperform” rating and issued a $30.00 price target on shares of Kiniksa Pharmaceuticals in a research report on Tuesday. TheStreet upgraded shares of Kiniksa Pharmaceuticals from a “d+” rating to a “c” rating in a research report on Thursday, February 29th.

Kiniksa Pharmaceuticals Stock Up 4.3 %

NASDAQ KNSA traded up $0.73 during midday trading on Tuesday, hitting $17.82. The company had a trading volume of 417,949 shares, compared to its average volume of 399,899. The stock has a market cap of $1.26 billion, a price-to-earnings ratio of 100.28 and a beta of 0.27. The firm has a fifty day simple moving average of $19.40 and a two-hundred day simple moving average of $18.00. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $10.65 and a fifty-two week high of $22.09.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings data on Wednesday, February 28th. The company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.15. The company had revenue of $83.40 million during the quarter, compared to the consensus estimate of $72.31 million. Kiniksa Pharmaceuticals had a net margin of 5.11% and a negative return on equity of 6.12%. As a group, equities analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.06 earnings per share for the current year.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.